Mirtazapine is an antidepressant prescribed primarily for major depressive disorder, but its unusual pharmacological profile gives it a range of off-label uses that few other antidepressants can match. It boosts appetite, promotes sleep, eases nausea, and relieves chronic itch, all as side effects of the same receptor activity that makes it work against depression. That versatility has made it a go-to medication when clinicians need to address several problems at once, particularly in patients who are depressed, underweight, and sleeping poorly.
How Mirtazapine Works
Mirtazapine belongs to a class called noradrenergic and specific serotonergic antidepressants. It works by blocking certain receptors that normally throttle the release of norepinephrine and serotonin, effectively increasing the availability of both neurotransmitters in the brain. At the same time, it selectively blocks specific serotonin receptor subtypes (5-HT2 and 5-HT3) while leaving 5-HT1A transmission intact.1PubMed Central. A review of the pharmacological and clinical profile of mirtazapine That selective blockade is key: by avoiding the serotonin receptors responsible for sexual dysfunction, nausea, and agitation, mirtazapine sidesteps many of the side effects that plague SSRIs.
What drives many of mirtazapine’s secondary uses is its strong affinity for histamine H1 receptors. Brain imaging studies in healthy volunteers show that mirtazapine occupies roughly 80 to 90 percent of histamine H1 receptors in the brain’s cortex, which directly correlates with subjective sleepiness.2PubMed. Histamine H₁ receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers Histamine blockade also stimulates appetite and reduces itching, which explains why a single drug can address such a wide range of complaints.
Depression and Speed of Onset
As a first-line antidepressant, mirtazapine performs on par with SSRIs overall. A meta-analysis comparing the two classes found pooled response rates of about 67 percent for mirtazapine and 62 percent for SSRIs, a difference that was not statistically significant.3PubMed. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Where mirtazapine distinguishes itself is in how quickly it starts working. A Cochrane review of 12 trials found mirtazapine was significantly more effective than SSRIs at the two-week mark.4PubMed Central. Mirtazapine versus other antidepressive agents for depression
That early advantage has been confirmed in head-to-head comparisons. In one prospective trial against sertraline, mirtazapine produced significantly greater improvement on depression rating scales at every assessment during the first two weeks.5Journal of Clinical Psychopharmacology. Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study A large naturalistic study of nearly 4,800 patients confirmed the pattern: the biggest improvement came in the first two weeks, with further gains slowing after that.6PubMed Central. Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients For someone in crisis or for whom a previous antidepressant took weeks to show any effect, that faster initial response can be meaningful.
Sleep and Insomnia
Clinicians have used mirtazapine informally for insomnia for years, and recent randomized trials have started to validate that practice. In the DREAMING trial, a placebo-controlled study run in general practice, low-dose mirtazapine produced recovery rates of 56 percent at six weeks compared to 14 percent for placebo. Participants on mirtazapine also slept roughly an hour longer per night, an effect that persisted at twelve weeks.7PubMed Central. Effectiveness of low-dose amitriptyline and mirtazapine in patients with insomnia disorder and sleep maintenance problems: a randomised, double-blind, placebo-controlled trial in general practice (DREAMING) The MIRAGE trial focused specifically on older adults with chronic insomnia and found mirtazapine significantly improved time spent awake after falling asleep, total sleep time, and sleep efficiency.8Age and Ageing. Mirtazapine for chronic insomnia in older adults: a randomised double-blind placebo-controlled trial—the MIRAGE study
Even in people without depression, short-term use at low doses has shown benefits. A crossover trial in healthy volunteers found that mirtazapine increased total sleep time by about half an hour and reduced nighttime awakenings by 35 to 40 percent under conditions designed to disrupt sleep.9PubMed. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial Beyond simply getting people to sleep, mirtazapine also changes sleep architecture in ways that may be beneficial for depression. In depressed patients, it increased slow-wave sleep (the deep, restorative stage) and lengthened the delay before the first REM period.10PubMed. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine Since depression is often associated with too much REM sleep too early in the night, that shift in sleep structure may contribute to the antidepressant effect itself.
Appetite Stimulation and Weight Gain
Weight gain is one of mirtazapine’s most common side effects, and in the right clinical context, that side effect becomes the whole point. Patients with cancer-related wasting, chronic illness, or severe appetite loss from other causes are sometimes prescribed mirtazapine specifically to regain weight. In a randomized trial of advanced cancer patients, 35 percent of those taking mirtazapine gained at least one kilogram after eight weeks.11Japanese Journal of Clinical Oncology. Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial That might sound modest, but in patients experiencing progressive weight loss from cancer, any reversal of the trend is clinically meaningful.
The appetite-stimulating effect likely comes from the same histamine blockade that causes sedation. Antihistamines as a class tend to increase appetite, and mirtazapine’s high affinity for H1 receptors makes this effect particularly pronounced. It is worth knowing that the appetite boost tends to be strongest in the first few weeks of treatment and often plateaus. For people being prescribed mirtazapine for depression who are not underweight, this side effect can be unwelcome, and it is one of the more common reasons patients ask to switch medications.
Nausea and Gastroparesis
Mirtazapine’s blockade of 5-HT3 receptors gives it anti-nausea properties similar to those of ondansetron, the anti-emetic commonly given after surgery and chemotherapy. This has led clinicians to try it for gastroparesis, a condition where the stomach empties too slowly, causing persistent nausea, vomiting, and early fullness. Case reports describe patients with gastroparesis that did not respond to conventional treatments experiencing near-complete symptom relief after starting mirtazapine, sometimes able to tolerate solid food within a day or two.12PubMed Central. Mirtazapine for Refractory Gastroparesis The evidence here is still limited to case reports and small series rather than large trials, but for patients who have run out of other options, it represents a meaningful last resort. The drug may also help with functional nausea and cyclic vomiting, conditions where the gut’s serotonin signaling appears to be disrupted.
Anxiety Disorders and PTSD
Although mirtazapine is not a first-line anxiety treatment, accumulating evidence suggests it works about as well as SSRIs for generalized anxiety disorder. A recent systematic review and meta-analysis found no significant difference between mirtazapine and SSRIs in reducing anxiety symptoms, and the same held true when comparing it to benzodiazepines.13PubMed. Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders: A Systematic Review and Meta-Analysis of Current Evidence For people who have both depression and anxiety, mirtazapine can address both without needing a separate anxiolytic.
In post-traumatic stress disorder, the picture is more nuanced. A small placebo-controlled trial of 29 outpatients with PTSD found a response rate of 65 percent for mirtazapine compared to 20 percent for placebo across several PTSD and general anxiety measures.14Psychiatry Investigation. Update on Current Treatment Options for Posttraumatic Stress Disorder The same meta-analysis mentioned above also found evidence that adding mirtazapine to an SSRI could be effective as an augmentation strategy for PTSD. Given that SSRIs are the standard pharmacological treatment for PTSD and many patients only partially respond, the ability to add mirtazapine on top without duplicating the same mechanism is useful in practice.
Chronic Tension-Type Headache
One use that flies under the radar is headache prevention. A randomized, placebo-controlled trial in patients with chronic tension-type headache found that mirtazapine reduced headache burden (measured as the product of frequency and intensity) by 34 percent more than placebo. It also significantly reduced headache frequency, duration, and intensity as individual measures, and was well tolerated throughout the trial.15Neurology. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache These were patients who were difficult to treat, making the results more notable. The mechanism is likely related to both serotonin and norepinephrine modulation in pain pathways, the same principle behind other antidepressants used for headache prevention.
Chronic Itch
Mirtazapine has found a niche in treating chronic pruritus, particularly the kind that develops in kidney disease patients undergoing dialysis. Multiple reports and pilot studies have documented relief from uremic pruritus, a maddening form of itching that affects a substantial proportion of dialysis patients and responds poorly to topical treatments.16PubMed Central. Differential onset time of mirtazapine on pruritus and depression in a patient receiving hemodialysis A crossover pilot study in hemodialysis patients provided additional evidence that mirtazapine can be an effective therapy for this condition.17PubMed. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study The anti-itch effect traces back to histamine receptor blockade combined with 5-HT2 antagonism, both of which are involved in the sensation of itching. Beyond kidney disease, clinicians have tried it for pruritus related to liver disease and cancer, with some success reported in case series.
Alcohol Dependence and Withdrawal
When someone dependent on alcohol goes through detoxification, the withdrawal period is typically marked by anxiety, insomnia, and physical discomfort, all of which mirtazapine’s pharmacology is suited to address. A study found that mirtazapine used alongside short-term psychotherapy reduced physical and subjective discomfort during detoxification, potentially improving patient compliance with treatment programs.18PubMed. Mirtazapine improves alcohol detoxification In patients with alcohol dependence and co-occurring depression, an open-label study found that mirtazapine was associated with significant reductions in both depressive symptoms and alcohol craving, with craving scores dropping by over 40 percent.19PubMed. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study These are not the large placebo-controlled trials that would make mirtazapine a standard treatment for alcoholism, but they support its use when depression and alcohol problems overlap.
Dementia-Related Agitation
Whether mirtazapine can calm agitation in people with dementia has been a subject of conflicting evidence. A small pilot study of agitated Alzheimer’s patients found significant reductions in agitation scores after treatment with mirtazapine, with no cognitive worsening as a side effect.20PubMed Central. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study That looked promising, but the much larger and more rigorous SYMBAD trial, published in The Lancet, found no benefit whatsoever. In that randomized, double-blind, placebo-controlled study, agitation scores at 12 weeks were not significantly different between mirtazapine and placebo, leading the investigators to conclude plainly that their data do not support using mirtazapine as a treatment for agitation in dementia.21The Lancet. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial The lesson from these two studies is a familiar one in clinical research: early small positive results do not always hold up when tested rigorously.
Use in Cats
One of mirtazapine’s more unexpected roles is in veterinary medicine. Cats with chronic kidney disease, cancer, or other wasting conditions often stop eating, and mirtazapine has become a standard appetite stimulant in feline practice. A transdermal ointment applied to the inner ear flap is now FDA-approved for cats, sidestepping the difficulty of getting a sick cat to swallow a pill. In a placebo-controlled study, cats receiving the transdermal mirtazapine gained an average of about 4 percent of their body weight, compared to essentially no change in the placebo group.22PubMed Central. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss Studies in cats with chronic kidney disease specifically confirmed appetite stimulation and weight gain with the transdermal formulation.23PubMed Central. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease If your veterinarian prescribes mirtazapine for your cat, the dosing is far lower than in humans and needs to be carefully managed, as cats metabolize drugs differently and are sensitive to overdose.
Side Effects and Metabolic Concerns
The side-effect profile of mirtazapine is distinct from SSRIs in ways that can be either advantages or drawbacks depending on the patient. Sedation and weight gain are the most common complaints, and both are tied to the same histamine blockade that makes the drug useful for insomnia and poor appetite. In clinical practice, sedation tends to diminish over the first few weeks as the body adjusts, though some people remain drowsy at higher doses.
A less well-known concern is mirtazapine’s effect on blood lipids. In a controlled study of healthy men, just seven days of mirtazapine at 30 mg produced a significant rise in triglycerides and a drop in HDL cholesterol, independent of any weight change. The researchers described this as a direct pharmacological effect on lipid metabolism, not merely a consequence of eating more.24PubMed Central. Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men An earlier study also found that mirtazapine was associated with increased total cholesterol, though it did not raise LDL specifically or worsen the ratio of total cholesterol to HDL.25The Journal of Clinical Psychiatry. The Effects of Mirtazapine on Plasma Lipid Profiles in Healthy Subjects For someone already at cardiovascular risk, these lipid changes are worth monitoring. In practice, clinicians should check lipid panels periodically in patients on long-term mirtazapine, especially those gaining weight.
On the other hand, mirtazapine is notably lower in sexual side effects than SSRIs, which is a significant quality-of-life advantage for many patients. It also causes less nausea than SSRIs, for the same 5-HT3 blockade reason that makes it useful against gastroparesis.
Drug Interactions
Mirtazapine is broken down in the liver by multiple enzyme pathways, primarily CYP2D6, CYP1A2, and CYP3A4.26Drug Metabolism and Disposition. Metabolism of the Antidepressant Mirtazapine in Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4 Because several enzymes share the workload, inhibiting any single one usually does not cause dramatic spikes in mirtazapine levels. This makes it somewhat forgiving compared to drugs that rely on a single pathway. Still, strong inhibitors of CYP3A4 (like ketoconazole, an antifungal, or certain HIV protease inhibitors) can meaningfully slow mirtazapine clearance and increase side effects. Heavy cigarette smoking induces CYP1A2 and can lower mirtazapine levels, while quitting smoking can cause levels to rise. Patients who are both poor CYP2D6 metabolizers and taking a CYP3A4 inhibitor are at the greatest risk of accumulating the drug.
Pregnancy, Lactation, and Stopping the Drug
The safety data for mirtazapine in pregnancy are limited but generally reassuring for major birth defects. A systematic review of 390 exposed pregnancies found no increased risk of major malformations associated with mirtazapine. There were some conflicting findings around spontaneous abortion, though this may reflect the underlying psychiatric illness rather than the drug itself.27PubMed. Mirtazapine in pregnancy and lactation – A systematic review A more recent systematic review reached a similar conclusion: outcomes in exposed pregnancies were generally comparable to controls, though data on late-pregnancy exposure suggested the possibility of neonatal adaptation syndrome, a temporary withdrawal-like reaction in newborns.28PubMed Central. Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes For breastfeeding, the limited available data suggest low infant exposure, but data remain scarce. The decision to use mirtazapine during pregnancy always involves weighing the risks of untreated depression against the uncertainties of fetal exposure, and that conversation is best had with a prescriber who knows the full clinical picture.
Stopping mirtazapine abruptly after more than a few weeks can produce withdrawal symptoms including nausea, dizziness, headaches, sleep disruption, anxiety, and irritability. Gradual tapering over several weeks is the standard recommendation. Unusually, some case reports describe pruritus, an ironic reversal of one of its therapeutic uses, emerging after sudden discontinuation.29PubMed Central. Pruritus associated with abrupt mirtazapine discontinuation: Single case report The withdrawal profile is generally considered milder than that of SSRIs with short half-lives, like paroxetine and venlafaxine, but stopping any antidepressant cold turkey is a bad idea. If you want to come off mirtazapine, work with your prescriber to set a tapering schedule.